Clinical Trial Update: A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing FF/UMEC/VI single inhaler triple therapy to tiotropium alone in COPD patients; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Furoate/ Umeclidinium/ Vilanterol
• tiotropium (tiotropium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2020-04-24